HCPCS Level II
Q5119
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
Codes near Q5119
These sit next to Q5119 in the CMS Level II file. All Q codes
- Q5114Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg
- Q5115Injection, rituximab-abbs, biosimilar, (truxima), 10 mg
- Q5116Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg
- Q5117Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg
- Q5118Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
- Q5120Injection, pegfilgrastim-bmez (ziextenzo), biosimilar, 0.5 mg
- Q5121Injection, infliximab-axxq, biosimilar, (avsola), 10 mg
- Q5122Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg
- Q5123Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
- Q5124Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg
NDC crosswalk
| NDC | Drug | Labeler | Billable units |
|---|---|---|---|
| 00069-0238-01 | Ruxience | Pfizer Inc | 10 |
| 00069-0249-01 | Ruxience | Pfizer Inc | 50 |
Source: CMS ASP NDC-HCPCS crosswalk, effective October 1, 2026 through December 31, 2026.